Cargando…

A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance

BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalis...

Descripción completa

Detalles Bibliográficos
Autores principales: Anisul, Mohd, Shilts, Jarrod, Schwartzentruber, Jeremy, Hayhurst, James, Buniello, Annalisa, Shaikho Elhaj Mohammed, Elmutaz, Zheng, Jie, Holmes, Michael, Ochoa, David, Carmona, Miguel, Maranville, Joseph, Gaunt, Tom R, Emilsson, Valur, Gudnason, Vilmundur, McDonagh, Ellen M, Wright, Gavin J, Ghoussaini, Maya, Dunham, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457835/
https://www.ncbi.nlm.nih.gov/pubmed/34402426
http://dx.doi.org/10.7554/eLife.69719
_version_ 1784571188117241856
author Anisul, Mohd
Shilts, Jarrod
Schwartzentruber, Jeremy
Hayhurst, James
Buniello, Annalisa
Shaikho Elhaj Mohammed, Elmutaz
Zheng, Jie
Holmes, Michael
Ochoa, David
Carmona, Miguel
Maranville, Joseph
Gaunt, Tom R
Emilsson, Valur
Gudnason, Vilmundur
McDonagh, Ellen M
Wright, Gavin J
Ghoussaini, Maya
Dunham, Ian
author_facet Anisul, Mohd
Shilts, Jarrod
Schwartzentruber, Jeremy
Hayhurst, James
Buniello, Annalisa
Shaikho Elhaj Mohammed, Elmutaz
Zheng, Jie
Holmes, Michael
Ochoa, David
Carmona, Miguel
Maranville, Joseph
Gaunt, Tom R
Emilsson, Valur
Gudnason, Vilmundur
McDonagh, Ellen M
Wright, Gavin J
Ghoussaini, Maya
Dunham, Ian
author_sort Anisul, Mohd
collection PubMed
description BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets. RESULTS: Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability >0.9, p=1 × 10(-4)), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal is highly pleiotropic, and a look-up of proteins associated with the ABO signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. CONCLUSIONS: Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19. FUNDING: MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
format Online
Article
Text
id pubmed-8457835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-84578352021-09-24 A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance Anisul, Mohd Shilts, Jarrod Schwartzentruber, Jeremy Hayhurst, James Buniello, Annalisa Shaikho Elhaj Mohammed, Elmutaz Zheng, Jie Holmes, Michael Ochoa, David Carmona, Miguel Maranville, Joseph Gaunt, Tom R Emilsson, Valur Gudnason, Vilmundur McDonagh, Ellen M Wright, Gavin J Ghoussaini, Maya Dunham, Ian eLife Epidemiology and Global Health BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets. RESULTS: Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability >0.9, p=1 × 10(-4)), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal is highly pleiotropic, and a look-up of proteins associated with the ABO signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. CONCLUSIONS: Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19. FUNDING: MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. eLife Sciences Publications, Ltd 2021-08-17 /pmc/articles/PMC8457835/ /pubmed/34402426 http://dx.doi.org/10.7554/eLife.69719 Text en © 2021, Anisul et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Epidemiology and Global Health
Anisul, Mohd
Shilts, Jarrod
Schwartzentruber, Jeremy
Hayhurst, James
Buniello, Annalisa
Shaikho Elhaj Mohammed, Elmutaz
Zheng, Jie
Holmes, Michael
Ochoa, David
Carmona, Miguel
Maranville, Joseph
Gaunt, Tom R
Emilsson, Valur
Gudnason, Vilmundur
McDonagh, Ellen M
Wright, Gavin J
Ghoussaini, Maya
Dunham, Ian
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title_full A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title_fullStr A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title_full_unstemmed A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title_short A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
title_sort proteome-wide genetic investigation identifies several sars-cov-2-exploited host targets of clinical relevance
topic Epidemiology and Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457835/
https://www.ncbi.nlm.nih.gov/pubmed/34402426
http://dx.doi.org/10.7554/eLife.69719
work_keys_str_mv AT anisulmohd aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT shiltsjarrod aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT schwartzentruberjeremy aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT hayhurstjames aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT bunielloannalisa aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT shaikhoelhajmohammedelmutaz aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT zhengjie aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT holmesmichael aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT ochoadavid aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT carmonamiguel aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT maranvillejoseph aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT gaunttomr aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT emilssonvalur aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT gudnasonvilmundur aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT mcdonaghellenm aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT wrightgavinj aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT ghoussainimaya aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT dunhamian aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT anisulmohd proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT shiltsjarrod proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT schwartzentruberjeremy proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT hayhurstjames proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT bunielloannalisa proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT shaikhoelhajmohammedelmutaz proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT zhengjie proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT holmesmichael proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT ochoadavid proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT carmonamiguel proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT maranvillejoseph proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT gaunttomr proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT emilssonvalur proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT gudnasonvilmundur proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT mcdonaghellenm proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT wrightgavinj proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT ghoussainimaya proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance
AT dunhamian proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance